The purpose of this study is to evaluate the difference in overall survival between dogs with splenic hemangiosarcoma (HSA) treated with splenectomy, Immunocidin (a non-specific immunotherapeutic), and concurrent doxorubicin, compared to those treated with standard of care (splenectomy and doxorubicin).
Your dog may qualify if:
- he/she has been diagnosed with splenic HSA,
- has had a splenectomy,
- has no evidence of disease spread,
- is otherwise healthy,
- has received no prior chemotherapy or immunotherapy.
If you agree to participate in this study, your pet will be randomized to receive standard of care (5 doses of doxorubicin given every 2 weeks) or doxorubicin and the new immunotherapeutic (both drugs are given on the same day for 5 doses, two weeks apart).
All treatments must be completed at Iowa State University. Both the chemotherapy and the immunotherapy are given IV into a vein in one of the legs. Patients will be monitored for two hours after the drugs have been given with non-invasive blood pressure, temperature, pulse, and respiratory measurements. Thus, be prepared for treatment days to take most of the day.
Blood work will be obtained prior to each treatment, and will be required one week following the first two treatments (this blood work does NOT need to be done at ISU).
By participating in this study, several aspect's of your dog's medical care will be provided at no cost to you.
If your dog is randomized to the immunotherapy arm of the study, you will receive the IV immunotherapy free of charge. In addition, all dogs enrolled, regardless of treatment regimen, will receive $60 for each of the 5 visits to help off-set the costs of the doxorubicin.
You will continue to be responsible for all other costs associated with your dog's treatment, including examination fees, blood work fees, restaging with chest x-rays and abdominal ultrasounds as recommended, the treatment of any complications that may arise, and unrelated medical conditions.
Dr Margaret Musser: 515-294-4900